Efficacy of intravenous clonazepam for paediatric convulsive status epilepticus

Dev Med Child Neurol. 2024 Aug;66(8):1053-1061. doi: 10.1111/dmcn.15859. Epub 2024 Jan 23.

Abstract

Aim: To compare the efficacy of intravenous clonazepam (CLZ) for the initial management of convulsive status epilepticus (CSE) in children as a function of the first-line in-hospital dose used.

Method: This monocentric retrospective study included children who received a first dose of CLZ for CSE at Montpellier University Hospital, France, between January 2016 and June 2019. Data from medical records (clinical, treatment, course) were collected and compared as a function of the first CLZ dose used.

Results: Among the 310 children treated for CSE, 105 received at least one CLZ dose (median age 3 years; quartile 1-quartile 3 [Q1-Q3] = 1 years 2 months-6 years 6 months). Among these 105 patients, 24 (22%) received a dose less than 0.03 mg/kg (low dose) and 69 (65%) received a dose of at least 0.03 mg/kg (high dose). Seizure cessation rate was not different between the low- and high-dose groups (62.5% vs 76%; odds ratio 0.53, 95% confidence interval [CI] 0.19-1.44, p = 0.29). The administration of a second dose of CLZ was more frequent in the low- than the high-dose group (37.5% vs 16%; odds ratio 3.2, 95% CI 1.1-9.1, p = 0.04).

Interpretation: Our study did not find any difference in seizure termination rate as a function of CLZ dose in children with CSE. However, a second CLZ dose was more frequently needed in the group receiving low (less than 0.03 mg/kg) CLZ.

MeSH terms

  • Administration, Intravenous*
  • Anticonvulsants* / administration & dosage
  • Child
  • Child, Preschool
  • Clonazepam* / administration & dosage
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Infant
  • Male
  • Retrospective Studies
  • Status Epilepticus* / drug therapy
  • Treatment Outcome

Substances

  • Clonazepam
  • Anticonvulsants